Research progress of peripheral blood miRNA in Alzheimer's disease

doi:10.3877/cma.j.issn.2095-8757.02.007

Abstract

Abstract:

Clinical diagnosis of Alzheimer’s disease (AD) is difficult in early stages. Reliable biomarkers are required for diagnosis of AD. The detection of miRNAs which is stable in peripheral blood is an ideal means of performing early screening because of its convenience, non-invasiveness, and suitability for screening large populations. This paper introduces the miRNAs detection in serum, blood mononuclear cells, whole blood or plasma in Alzheimer's disease, providing a new method for AD diagnosis.

Key words: Alzheimer’s disease, micro RNA, Peripheral blood

Juan Xu, Jing Xu, Ran Meng, Yuanyuan Zhao, Wei Zheng, Yuquan Wu. Research progress of peripheral blood miRNA in Alzheimer's disease[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2017, 04(02): 39-42.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.02.007

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2017/V04/I02/39

References 31

[1]	Cordell CB, Borson S, Boustani M, et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting[J].Alzheimers Dement, 2013, 9(2): 141-150.
[2]	Sabbagh MN. Drug development for Alzheimer's disease: where are we now and where are we headed[J]? Am J Geriatr Pharmacother, 2009, 7(3): 167-185.
[3]	Dickson JR, Kruse C, Montagna DR, et al. Alternative polyadenylation and miR-34 family members regulate tau expression[J]. J Neurochem, 2013, 127(6): 739-749.
[4]	Dong H, Li J, Huang L, et al. Serum microRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer's disease[J]. Dis Markers, 2015, 2015: 625659.
[5]	Esquela-Kerscher A, Slack FJ, Oncomirs-microRNAs with a role in cancer[J]. Nat Rev Cancer, 2006, 6(4): 259-269.
[6]	Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease[J]? Circ Res, 2012, 110(3): 483-495.
[7]	Jung HJ, Suh Y. Circulating miRNAs in ageing and ageing-related diseases[J]. J Genet Genomics, 2014, 41(9): 465-472.
[8]	Noren Hooten N, Fitzpatrick M, Wood WH, et al. Age-related changes in microRNA levels in serum[J]. Aging (Albany NY), 2013, 5(10): 725-740.
[9]	Turchinovich A, Samatov TR, Tonevitsky AG, et al. Circulating miRNAs: cell-cell communication function[J]? Front Genet, 2013, 4:119.
[10]	Grasso M, Piscopo P, Confaloni A, et al. Circulating miRNAs as biomarkers for neurodegenerative disorders[J]. Molecules, 2014, 19(5): 6891-6910.
[11]	He Y, Lin J, Kong D, et al. Current state of circulating microRNAs as cancer biomarkers[J]. Clin Chem, 2015, 61(9): 1138-1155.
[12]	Ma R, Jiang T, Kang X. Circulating microRNAs in cancer: origin, function and application[J]. J Exp Clin Cancer Res, 2012, 31: 38.
[13]	Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer[J]. Nat Rev Clin Oncol, 2014, 11(3): 145-156.
[14]	Geekiyanage H, Chan C. MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloidβ, novel targets in sporadic Alzheimer's disease[J]. J Neurosci, 2011, 31(41): 14820-14830.
[15]	Geekiyanage H, Jicha GA, Nelson PT, et al. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease[J]. Exp Neurol, 2012, 235(2): 491-496.
[16]	Wu Y, Xu J, Xu J, et al. Lower Serum Levels of miR-29c-3p and miR-19b-3p as biomarkers for Alzheimer's disease[J]. Tohoku J Exp Med, 2017, 242(2): 129-136.
[17]	Galimberti D, Villa C, Fenoglio C, et al. Circulating miRNAs as potential biomarkers in Alzheimer's disease[J]. J Alzheimers Dis, 2014, 42(4): 1261-1267.
[18]	Sheinerman KS, Umansky SR. Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies[J]. Front Cell Neurosci, 2013, 7: 150.
[19]	Tan L, Yu JT, Liu QY, et al. Circulating miR-125b as a biomarker of Alzheimer's disease[J]. J Neurol Sci, 2014, 336(1-2):52-56.
[20]	Tan L, Yu JT, Tan MS, et al. Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease[J]. J Alzheimers Dis, 2014, 40(4): 1017-1027.
[21]	Schipper HM, Maes OC, Chertkow HM, et al. MicroRNA expression in Alzheimer blood mononuclear cells[J]. Gene Regul Syst Bio, 2007, 1: 263-274.
[22]	Bhatnagar S, Chertkow H, Schipper HM, et al. Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma[J]. Front Mol Neurosci, 2014, 7: 2.
[23]	La Fauci G, Lahiri DK, Salton SR, et al. Characterization of the 5'-end region and the first two exons of the beta-protein precursor gene[J]. Biochem Biophys Res Commun, 1989, 159(1):297-304.
[24]	Heicklen-Klein A, Ginzburg I. Tau promoter confers neuronal specificity and binds Sp1 and AP-2[J]. J Neurochem, 2000, 75(4): 1408-1418.
[25]	Villa C, Ridolfi E, Fenoglio C, et al. Expression of the transcription factor Sp1 and its regulatory hsa-miR-29b in peripheral blood mononuclear cells from patients with Alzheimer's disease[J].J Alzheimers Dis, 2013, 35(3): 487-494.
[26]	Satoh J, Kino Y, Niida S. MicroRNA-seq data analysis pipeline to identify blood biomarkers for Alzheimer's disease from public data[J]. Biomark Insights, 2015, 10: 21-31.
[27]	Kumar P, Dezso Z, MacKenzie C, et al. Circulating miRNA biomarkers for Alzheimer's disease[J]. PLoS One, 2013, 8(7): e69807.
[28]	Bekris LM, Lutz F, Montine TJ, et al. MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma[J]. Biomarkers, 2013, 18(5): 455-466.
[29]	刘辰庚，王金玲，李蕾，等.阿尔茨海默病患者血液标本外吐小体中miRNA-135a的检测[J].现代生物医学进展, 2013, 13(22): 4361-4363.
[30]	Lugli G, Cohen AM, Bennett DA, et al. Plasma exosomal miRNAs in persons with and without Alzheimer's disease: altered expression and prospects for biomarkers[J]. PLoS One, 2015, 10(10): e0139233.
[31]	Cheng L, Doecke JD, Sharples RA, et al. Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment[J].Mol Psychiatry, 2015, 20(10): 1188-1196.

Please choose a citation manager

Content to export